Inhibikase Therapeutics (IKT)
NASDAQ:IKT
Want to see IKT full AI Analyst Report?
IKT Stock Chart & Stats
$1.70
$0.06(1.71%)
At close: 4:00 PM EST
$1.70
$0.06(1.71%)
Day’s Range― - ―
52-Week Range$1.33 - $2.37
Previous CloseN/A
Volume38.02K
Average Volume (3M)132.72K
Market Cap
$236.34M
Enterprise Value-$9.28M
Total Cash (Recent Filing)$178.76M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.50
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding132,032,640
10 Day Avg. Volume124,469
30 Day Avg. Volume132,718
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.17
Price to Sales (P/S)0.00
P/FCF Ratio-7.25
Enterprise Value/Market Cap-0.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit95.41
Enterprise Value/Ebitda0.18
Forecast
1Y Price Target
$6.20Price Target Upside264.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.4
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementEnrollment of the first patient in the pivotal Phase 3 study advances the registrational program and reduces development uncertainty for the therapy.
Prodrug TolerabilityIKT-001's prodrug design aims to deliver active imatinib with reduced gastrointestinal toxicity, which could enable higher tolerated dosing and improve treatment adherence.
Regulatory Flexibility And Trial DesignRegulatory acceptance of an adaptive two-part study that permits dose titration and sample size re-estimation provides flexibility to optimize dosing and bolster the chance of a successful outcome.
Bears Say
Competitive PressureFirst-mover adoption of an alternative approved therapy could limit prescribing and market share for the company's candidate, constraining commercial opportunity despite potential add-on use.
Delivery Method UncertaintyQuestions about whether local or inhaled delivery can achieve sufficient systemic exposure create scientific risk that could undermine efficacy expectations for tyrosine kinase inhibitor approaches relying on non-systemic administration.
Funding And Dilution RiskLarge development costs for late-stage testing increase the likelihood of future financing needs that could dilute existing shareholders if additional capital is required.
Inhibikase Therapeutics News
IKT FAQ
What was Inhibikase Therapeutics’s price range in the past 12 months?
Inhibikase Therapeutics lowest stock price was $1.33 and its highest was $2.37 in the past 12 months.
What is Inhibikase Therapeutics’s market cap?
Inhibikase Therapeutics’s market cap is $236.34M.
When is Inhibikase Therapeutics’s upcoming earnings report date?
Inhibikase Therapeutics’s upcoming earnings report date is May 18, 2026 which is in 30 days.
How were Inhibikase Therapeutics’s earnings last quarter?
Inhibikase Therapeutics released its earnings results on Mar 26, 2026. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.103 by $0.003.
Is Inhibikase Therapeutics overvalued?
According to Wall Street analysts Inhibikase Therapeutics’s price is currently Undervalued.
Does Inhibikase Therapeutics pay dividends?
Inhibikase Therapeutics does not currently pay dividends.
What is Inhibikase Therapeutics’s EPS estimate?
Inhibikase Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Inhibikase Therapeutics have?
Inhibikase Therapeutics has 132,032,640 shares outstanding.
What happened to Inhibikase Therapeutics’s price movement after its last earnings report?
Inhibikase Therapeutics reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.103. Following the earnings report the stock price went up 3.067%.
Which hedge fund is a major shareholder of Inhibikase Therapeutics?
Currently, no hedge funds are holding shares in IKT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inhibikase Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.20 (264.71% Upside)
$6.20 (264.71% Upside)
Hedge Fund Trend
Increased
By 5.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 5.8%
Last 30 Days ▼ 5.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.19%
12-Months-Change
Fundamentals
Return on Equity
-46.90%
Trailing 12-Months
Asset Growth
83.78%
Trailing 12-Months
Company Description
Inhibikase Therapeutics
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
IKT Stock 12 Month Forecast
Average Price Target
$6.20
▲(264.71% Upside)
Technical Analysis
Atossa Therapeutics
―
Anixa Biosciences
―
Spero Therapeutics
―
Surrozen
―
TScan Therapeutics
―